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Increased tubular organic ion clearance following chronic ACE
inhibition in patients with type 1 diabetes.
Background. The tubular excretion of creatinine significantly
contributes to its clearance. Administration of an angtiotensin-
converting enzyme (ACE) inhibitor is associated with increased
organic ion clearance in experimental diabetes. This study ex-
amines the effect and implications of chronic ACE inhibition
on renal organic ion excretion in patients with type 1 diabetes.
Methods. Samples were obtained from the Melbourne Di-
abetic Nephropathy Study Group (MDNSG) that randomized
patients to receive perindopril (N = 11), nifedipine (N = 11), or
placebo (N = 8). Albumin excretion rate, creatinine clearance,
and isotopic glomerular filtration rate (GFR) were assessed
at baseline and after 24 months. In addition, the clearance of
the endogenous cations N-methylynicotinamide (NMN), cre-
atinine, and the anion hippurate were determined by high-
performance liquid chromatography (HPLC).
Results. Following treatment with the ACE inhibitor,
perindopril, renal clearance of NMN was increased (+96%)
(P < 0.05). There was no difference in patients treated with
nifedipine (P = 0.25) and NMN clearance fell in the placebo-
treated patients (−26%) (P < 0.05). Changes in NMN clear-
ance were unaffected after adjusting for the effects of perindo-
pril on GFR. However, they were attenuated after adjusting
for hippurate clearance, a marker of renal blood flow. This ef-
fect of perindopril on NMN clearance was seen in both men
and women, regardless of baseline clearance and was correlated
with reduced albuminuria following perindopril treatment.
Conclusion. Organic ion clearance is increased in patients
with diabetes following chronic ACE inhibition. This is con-
sistent with experimental models showing increased ion trans-
porter expression and improved tubular blood flow, following
blockade of the renin-angiotensin system (RAS). These findings
may have implications for the interpretation of creatinine-based
indices in patients with diabetes.
1Study group investigators included T.J. Allen, D.J. Campbell, R.E.
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Conventional creatinine clearance systematically
overestimates glomerular filtration rate (GFR) by 10%
to 40% [1] because of creatinine secretion in the cor-
tical proximal tubule via organic cation transporter–
dependent pathways [2]. This secretory component to
creatinine clearance may be proportionately even greater
in advanced renal disease [1], liver disease [3], and
following renal transplantation [4]. Tubular creatinine
excretion is blocked by cimetidine and trimethoprim,
contributing to the increase in serum creatinine observed
in patients treated with these compounds in the ab-
sence of any change in iothalamate GFR [5, 6]. The
renin-angiotensin system (RAS) also has the potential to
influence the excretion of organic ions. We recently
demonstrated that administration of the angiotensin-
converting enzyme (ACE) inhibitor, ramipril, was
associated with increased organic cation clearance in ex-
perimental diabetes [7]. This may be related both to
changes in tubular blood flow and the restoration of
the expression of organic cation transporters, possibly
through its renoprotective actions. Changes are also ob-
served in organic anion excretion, where chronic ACE
inhibition increases the fractional tubular clearance of
hippurate. This is detected clinically as a reduction in the
filtration fraction following chronic ACE inhibition in pa-
tients with diabetes [8]. We hypothesize similar changes
in the clearance of renal organic ions may occur in pa-
tients with diabetes who are treated with ACE inhibitors
and, as a consequence, the tubular handling of creatinine
may be modified.
METHODS
Concurrent serum and urine samples were obtained
the Melbourne Diabetic Nephropathy Study Group
(MDNSG) comparing the efficacy of chronic ACE in-
hibition with calcium antagonism in normotensive pa-
tients with type 1 diabetes and microalbuminuria [9]. In
this study, outpatients from three university teaching hos-
pitals were randomized to receive perindopril (titrated
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to up to 8 mg daily), slow-release nifedipine (titrated
to 40mg twice a day), or placebo. In the first 3 months,
drug dosage was titrated to achieve a decrease in diastolic
blood pressure of at least 5 mm Hg: Thirty-three patients
had a minimum of 24 months’ data and were included in
this analysis. The clinical characteristics of these patients
have been previously described.
Creatinine clearance and isotopic GFR were mea-
sured on consecutive days, assessed at baseline and at
12 monthly intervals for 24 months. Creatinine clearance
was estimated by two methods: first, by the Cockroft-
Gault formula after adjustment for body surface area
and, second, from the timed (12-hour) urine collection.
The creatinine concentration of serum and urine samples
was measured by high performance liquid chromatogra-
phy (HPLC) [10]. Isotopic GFR was determined by the
iothalamate method and corrected using the Brochner-
Mortensen equation. Fractional tubular clearance of cre-
atinine was calculated as the proportion of total daily
excretion not achieved through glomerular filtration (1-
GFR/creatinine clearance).
Organic cation clearance was assessed by mea-
suring the clearance of the endogenous cation,
N-methylnicotinamide (NMN) utilizing the same timed
(12-hour collection) used for the determination of creati-
nine clearance. NMN has a pKa for the organic cation
transporter approximately 30 times that of creatinine
[11]. NMN concentrations of serum and urine samples
were determined by HPLC analysis, as previously de-
scribed [7, 12]. The clearance of NMN was estimated as
the excretion rate divided by the plasma concentration
(UV/P), expressed as milliliter per minute and corrected
for body surface area.
As creatinine may behave as a “zwitterions” at physio-
logic pH, allowing it to be secreted both through cationic
and anionic transporter pathways, organic anion clear-
ance was assessed using the clearance of the endoge-
nous anion, hippurate were determined by HPLC. Briefly,
300lL of acetonitrile containing the internal standard,
isopropanoic acid, was added drop-wise to 100 lL of
serum [13] or 1:50 diluted urine. The sample was then
centrifuged to remove precipitated protein and the su-
pernatant dried under nitrogen. Subsequently, the sam-
ple was reconstituted in a mobile phase consisting of 10%
acetonitrile, 1% trinitrofuran, and 0.5% phosphoric acid
[14]. The sample was then injected into a 250 × 3 mm,
5 l phenyl-hexyl column (Phenomenex, Torrance, CA,
USA) with a mobile phase at 1 mL/min. The hippurate
peak was detected at 10.2 minutes, using an on-line spec-
tophotometer set at 249 nm. The detection limit for this
method was 0.1 lg/mL. The interassay variability was
2.2% and interday variability was 5%. As serum and urine
were run sequentially, timed hippurate clearance was cal-
culated as the urinary volume multiplied by the area
under the urine hippurate curve divided by that of plasma
hippurate (UV/P), expressed as milliliter per minute per
1.73 m2 of body surface area.
Statistical tests
Organic ion clearance is presented as geometric mean
(range). Because of high baseline variability, patient re-
sults at 24 months are compared to baseline levels, ex-
pressed as the percentage change from baseline. The
Mann-Whitney rank sum test was used to examine dif-
ferences in urinary organic ion clearance between base-
line subgroups. Differences in continuous variables were
compared using the Wilcoxon signed rank test. Pearson
correlation was used to analyze univariate associations
between continuous variables. Subgroup analysis divided
patients above and below median group response.
RESULTS
Renal function
Renal function at the outset of the study was not signifi-
cantly different across the three groups (Table 1). During
the course of the 2-year follow-up, isotopic GFR declined
in all study groups by approximate 3% to 4%/year. By
contrast, urinary creatinine clearance only fell in patients
treated with nifedipine and placebo (−4%/year) (P <
0.05) but was not changed in the perindopril-treated pa-
tients (0%/year) (Table 1). Consequently, tubular clear-
ance of creatinine was increased in perindopril-treated
patients. However, because of the small patient numbers
and assay variability, none of these differences reached
significance.
Organic cation clearance
Baseline renal clearance of NMN in patients with type 1
diabetes was greater in men [537 mL/min/1.73 m2 (154 to
1374)] than women [218 mL/min/1.73 m2 (94 to 660)], con-
sistent with known gender differences in organic cation
transport [15]. In addition, there was a high level of
interindividual variability, as previously reported [16].
There was no clear relationship between NMN clearance
and renal function or albumin excretion rate at baseline.
Following treatment with the ACE inhibitor, perindo-
pril, renal clearance of NMN was significantly increased
from baseline (+96%) (P < 0.05). There was no signif-
icant difference from baseline in patients treated with
nifedipine (P = 0.25). However, renal NMN clearance
fell significantly in the placebo-treated patients (−26%)
(P < 0.05) (Fig. 1A). There was no significant effect of
baseline NMN clearance or gender in the response to
perindopril or placebo. Men and women responded sim-
ilarly in percentage terms, although absolute changes in
NMN clearance were 60% lower in women.
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Table 1. Renal function parameters before and after 2 years of intervention (mean ± SEM)
Placebo Placebo Perindopril Perindopril Nifedipine Nifedipine
Baseline 2 years Baseline 2 -years Baseline 2 years
Isotopic GFR mL/min/1. 73 m2 103 ± 8 94 ± 6 103 ± 6 97 ± 6 105 ± 5 96 ± 6
Cockroft-Gault mL/min/1.73 m2 113 ± 6 108 ± 4 111 ± 7 111 ± 6 111 ± 4 107 ± 5
Creatinine clearance mL/min/1.73 m2 112 ± 8 104 ± 4 113 ± 10 112 ± 6 115 ± 9 106 ± 7
Fractional tubular creatinine clearance% 9% 9% 10% 15% 10% 10%
GFR is glomerular filtration rate.
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Fig. 1. The effect of 2 years of treatment on treatment on baseline
N-methylnicotinamide (NMN) clearance (A) adjusted for isotopic
glomrular filtration rate (GFR) (B). ∗P < 0.05 vs. baseline.
The change in NMN clearance was not modified af-
ter adjusting for the differential effects of perindopril on
isotopic GFR (Fig. 1B). The only patient treated with
perindopril who experienced an apparent fall in NMN
clearance was normalized after adjusting for his signifi-
cant decline in GFR. This suggests the increased clear-
ance of NMN observed in these patients was determined
predominantly by increased tubular transport rather than
glomerular filtration. No significant difference could be
detected between nifedipine and placebo after adjusting
for changes in GFR in both groups.
There was a positive correlation between the change
in NMN clearance, in response to perindopril, and the
change in creatinine clearance over the 2-year study pe-
riod (R2 = 0.41, P < 0.01). Patients with the great-
est increase in their cation clearance (median response
for group, N = 6, cation responders) had a net in-
crease in creatinine clearance (2.5 mL/min/year), while
those with lesser responses (median response for group,
N = 5, cation nonresponders), had a net decline (−5
mL/min/year, between subgroups P = 0.05). However,
400%
300%
200%
100%
0%
−100%
−200%
Ch
an
ge
 fr
om
 b
as
el
in
e,
 %
Perindopril Nifedipine Placebo
Fig. 2. The effect of 2 years of treatment on treatment on baseline
hippurate clearance.
there was no significant correlation between NMN
clearance and the isotopic GFR response to perindopril.
There was, nonetheless, a much larger reduction in al-
bumin excretion rate (25%) in cation responders than
in nonresponders, following treatment with perindopril
(3.5%, between subgroups P < 0.05).
Organic anion clearance
Similar effects were observed in the clearance of the
endogenous anion, hippurate. Renal clearance of hippu-
rate was increased in patients treated with perindopril
and reduced in placebo-treated patients (Fig. 2). Like
NMN, there was a strong positive correlation between the
change in hippurate and creatinine clearances in patients
treated with perindopil (R = 0.7, P < 0.01). However,
this correlation was reversed in the other study groups
(R = −0.50, P = 0.03).
There was a correlation in the NMN and hippurate
clearance response in all groups (overall R2 = 0.62,
P < 0.01), such that patients experiencing the greatest in-
crease in NMN clearance also increased their clearance
of hippurate (Fig. 3). This was driven by the strong as-
sociation in the perindopril-treated patients (R2 = 0.7,
P < 0.01). Although patients treated with perindopril
and nifedipine roughly followed the same trend, this did
not reach statistical significance for either group (both
P = 0.1).
DISCUSSION
The renal excretion of organic ions appears to be sub-
stantially enhanced in patients with type 1 diabetes when
chronically treated with the ACE inhibitor, perindopril.
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Fig. 3. Correlation between N-methylnicotin-
amide (NMN) and hippurate clearance in pa-
tients with type 1 diabetes in patients treated
with perindopril Linear correlation. ∗P < 0.05,
#P = 0.1.
This effect was seen in both men and women and cor-
related with the known changes in creatinine clearance
and albuminuria seen with this agent. This phenomenon
is consistent with experimental studies showing that
blockade of the RAS in experimental diabetes increases
organic cation transporter–dependent NMN clearance,
despite ongoing polyuria and persistent hyperglycemia
[7].
It is acknowledged that the methods used in this survey
are only crude measures of renal organic ion transporter
pathways. Neither NMN nor hippurate are the optimal
markers of organic ion clearance, as both may undergo
renal metabolism [12, 16] and may be subject to distal re-
absorption [17]. Nonetheless, creatinine is also subject to
similar influences, such that changes in the renal clearance
of these organic anions may also reflect the tubular fate of
creatinine. The interindividual variability in NMN clear-
ance is also greater than that of creatinine [16], making
them inappropriate as a “one-off” screening for tubular
dysfunction. It is possible that serial measurements of or-
ganic ion clearance may be more useful in following both
the natural history of individuals with early diabetic kid-
ney disease and the results of therapeutic interventions.
The mechanism by which chronic ACE inhibition al-
ters organic ion excretion in patients with diabetes re-
mains to be established. Most ACE inhibitors and their
diacid metabolites are anionic and consequently cleared
by the kidneys via organic anion transporter pathways
[18]. While it is possible that these metabolites compete
with hippurate at the level of the organic anion trans-
porter, it is unlikely that interaction would increase crea-
tinine or NMN clearance. Indeed, probenecid, a selective
inhibitor of renal organic anion transport, may reduce
creatinine clearance [19].
We have previously shown that the ACE inhibitor,
ramipril, is able to increase the tubular expression of or-
ganic cation transporters in experimental diabetes [6].
It is conceivable that attenuation of renal damage, fol-
lowing chronic ACE inhibition, may be a factor in the
restoration of organic cation transporter expression. In-
deed, NMN clearance has been proposed as a marker
of tubular function in chronic renal disease [16]. Consis-
tent with this hypothesis, we have also recently demon-
strated that renoprotective therapy with the inhibitor of
advanced glycation, aminoguanidine, in diabetic animals
is also able to restore organic cation clearance to con-
trol levels [20]. Certainly, improvements in NMN clear-
ance in the MDNSG were correlated with albuminuria as
a marker of tubular injury. In addition, patients treated
with placebo had a significant fall in organic ion transport
over the 2-year study period, consistent with the decline in
organic ion transport previously described in experimen-
tal diabetes [6]. However, in experimental models at least,
the reduction in organic cation transport expression pre-
cedes the onset of proteinuria, and a reduction in cation
transport may be demonstrable after as little as one week
of experimental diabetes [21]. Rather than simple hemo-
dynamic changes, this would suggest a much more funda-
mental interaction between the chronic ACE inhibition
and organic cation transport. Angiotensin II has a direct
role in renal proximal tubular function, including acid-
ification, fluid absorption and transporter activity, pos-
sibly through the activation of protein kinase C (PKC).
The intrarenal RAS is known to be up-regulated in di-
abetic nephropathy and effects, including the induction
of PKC and cyclic guanosine monophosphate (cGMP),
are attenuated following chronic ACE inhibition [22].
A direct effect of Angiotensin II on organic cation
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transporter–mediated transport is also plausible, as or-
ganic cation accumulation is reduced in vitro, following
exposure to Angiotensin II in tubular cells [23].
Changes in tubular blood flow, associated with dia-
betes and manifested by an increased filtration fraction,
also serve to further reduce the fractional clearance of
organic ions like NMN and hippurate. It is well estab-
lished that blockade of the RAS in patients with diabetes
leads to an increase in renal plasma flow. The change
in NMN clearance could be partly, but not completely,
attenuated by correcting for changes in hippurate clear-
ance. This suggests that common mechanisms such as in-
creased renal blood flow may also be partly responsible
for these changes in organic ion clearance. This is further
supported by the reduction in NMN clearance and renal
blood flow observed experimentally, following an infu-
sion of angiotensin II, in the absence of any significant
change in organic cation transporter expression or GFR
[6].
Changes in the clearance of cationic compounds may
have important implications for the management of pa-
tients with diabetes. The organic cation transporters rep-
resent the first step in the active renal clearance of or-
ganic cations, like NMN, as well as a broad range of
endogenous molecules that include creatinine, steroids,
catecholamines, and their O-methylated monoamine
metabolites [11]. In addition, the organic cation trans-
porters are involved in the active tubular uptake of a num-
ber of toxins and drugs, including metformin and beta
blockers. Any reduction in organic ion clearance could
see the accumulation of charged organic compounds. In
particular, this may have important implications for the
interpretation of creatinine-based end points (creatinine
clearance, 1/creatinine, doubling of serum creatinine).
For example, in the Modification of Diet in Renal Dis-
ease (MDRD) study, protein restriction failed to corre-
late with changes in GFR but significantly influenced
creatinine clearance. This lead to the suggestion that
“tubular clearance of creatinine may be a more impor-
tant determinant of longitudinal serum creatinine levels
than changes in GFR” [24].
ACE inhibitors slow the rate of decline in creatinine
clearance in patients with diabetic nephropathy. It is pos-
sible that least some of the benefit attributed to this ther-
apy may also be related to improved tubular secretion
of creatinine. Indeed, the early improvements in creati-
nine clearance seen in ACE inhibitor studies that persists
at approximately the same level for many years without
further divergence from placebo may represent improved
tubular creatinine clearance. In our study, there was no
difference between patients in the MDNSG (treated ei-
ther with perindopril, nifedipine, or placebo) in terms of
changes to their GFR over the 2-year study period (both
−4%/year). However, creatinine clearance declined in
nifedipine- and placebo-treated patients (−4%/year),
and was not significantly changed in perindopril-treated
patients (0%/year). It should be noted that this small
study was not designed to detect changes in creatinine
clearance and much larger studies are required to test
this hypothesis.
CONCLUSION
The tubular clearance of organic ions is increased in
patients with diabetes following chronic treatment with
the ACE inhibitor, perindopril. This is consistent with
experimental models showing restoration of cation trans-
porter expression and improved tubular blood flow fol-
lowing chronic ACE inhibition. These findings may have
implications for the interpretation of creatinine-based
end points in patients with diabetes treated with ACE
inhibitors.
Reprint requests to Merlin C. Thomas, Baker Medical Re-
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